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LETTER TO THE EDITOR
Heritability of childhood leukaemia and non-Hodgkin lymphoma
Sir - We appreciate the interest that Dr Taylor (Taylor et
al., Br. J. Cancer (1996), 73, 847) has expressed in our paper
(Hawkins et al., Br. J. Cancer (1995), 71, 1335-1339).
However, we consider that the important cautions he raises
with regard to the interpretation of our findings were all
contained in the original paper or do not apply to this paper.
As we indicated in the introduction to the paper our
principal objective in writing the paper was to assess the
evidence concerning the heritability of these diseases; we shall
address the question of evidence for therapy-related germ cell
mutagenesis in a subsequent paper (see the final sentence of
the first paragraph of Materials and methods). In this
subsequent paper we shall examine the frequency of a
spectrum of adverse outcomes among the offspring of
survivors who were exposed/unexposed to therapy that may
be potentially germ cell mutagenic.
Dr Taylor reiterates a caution that we expressed in our
paper relating to the possibility of selection bias: 'This is not
entirely without problems of interpretation since it might be
that the group of patients who survive and produce offspring
may contain a different proportion of heritable cases to those
originally diagnosed'. In fact we have suggested this as a
possible explanation for the apparent increased risk of
Wilms' tumour among the offspring of survivors diagnosed
more recently as compared with offspring of survivors
diagnosed in an earlier period (Hlawkins et al., J. Natl
Cancer Inst. (1995) 87, 1323- 1324). Unfortunately, because
substantial survival after leukaemia is relatively recent
compared with that after Wilms' tumour there are
insufficient data to test this hypothesis.
Dr Taylor suggests that the assumed mode of inheritance
(autosomal dominant) is unlikely and the value proposed for
the penetrance is too high. In the paper we acknowledge that
less restrictive and more complicated modes of inheritance
might be hypothesised; however, we also note that these
would require much more data to test them adequately. In
the paper we give estimates of the proportion of survivors
with heritable disease assuming values for the penetrance
ranging from 0.2 to 1.0.
Dr Taylor concludes that the use of potentially biased data
to draw overall conclusions about the heritability of
leukaemia and non-Hodgkin lymphoma, about the germline
effects of radiation and for the purposes of genetic
counselling could be misleading.
As we indicated above we shall address the potential germ
cell mutagenic effects of radiotherapy and chemotherapy in a
subsequent paper. In the absence of any empirical evidence
for selection bias we consider that the conclusions drawn in
the paper in relation to heritability still stand and are perhaps
worth restating. 'The practical message to be derived from
this and previous studies is that, although any detailed
estimates of heritability depend on a number of unverified
assumptions, and although a degree of caution is necessary
until more offspring have been followed up, the empirically
observed risks to offspring are small'.
The data available at present are inevitably limited.
Nevertheless we believe it is important to analyse them and
to present, with appropriate qualifications, the conclusions
from such analyses.
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